ロード中...
Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy
The indications of immune checkpoint inhibitors (ICIs) are set to rise further with the approval of newer agent like atezolimumab for use in patients with advanced stage urothelial carcinoma. More frequent use of ICIs has improved our understanding of their unique side effects, which are known as im...
保存先:
| 出版年: | Front Pharmacol |
|---|---|
| 主要な著者: | , , , , , |
| フォーマット: | Artigo |
| 言語: | Inglês |
| 出版事項: |
Frontiers Media S.A.
2017
|
| 主題: | |
| オンライン･アクセス: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5296331/ https://ncbi.nlm.nih.gov/pubmed/28228726 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3389/fphar.2017.00049 |
| タグ: |
タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!
|